The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition
<p>Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding...
Main Authors: | Pedro Barata, Moshe C Ornstein, Jorge A Garcia |
---|---|
Format: | Article |
Language: | English |
Published: |
Codon Publications
2017-05-01
|
Series: | Journal of Kidney Cancer and VHL |
Subjects: | |
Online Access: | http://jkcvhl.com/index.php/jkcvhl/article/view/69 |
Similar Items
-
Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
by: Rohan Garje, et al.
Published: (2018-12-01) -
Inhibition of immune checkpoints and Vascular Endothelial Growth Factor as combination therapy for cancer: an overview of rationale, preclinical evidence, and initial clinical data
by: Patrick Alexander Ott, et al.
Published: (2015-09-01) -
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
by: Veronica Mollica, et al.
Published: (2019-06-01) -
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-04-01) -
Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?
by: Hung-Chih Lai, et al.
Published: (2019-05-01)